Abstract :
Lower urinary tract symptoms in males are mostly due to benign prostatic hyperplasia and overactive bladder. Approximately three-fourths of them require medical management with drugs like a1blockers and 5-a reductase inhibitors. Metabolic syndrome[MeS] as a comorbidity has been documented with a number of cases of benign prostatic hyperplasia [BPH]. The present study finds MeS as a potential risk factor for BPH and compares the effectiveness of BPH medications among those with and /or without underlying MeS. Patients were evaluated basing on the parameters like biochemical findings and clinical symptoms using IPSS Score, Quality of Life Score, prostate volume using Ultrasound abdomen and pelvis. Our study revealed that, waist circumference, BMI, FBS, Total Cholesterol, HDL cholesterol, LDL cholesterol & HOMA-IR were the significantly associated with the clinical outcome in the MetS ve patients having BPH. MetS significantly affects the response to medical treatment of BPH as revealed from the IPSS Score, prostate volume and quality of life index. It also emphasizes that MetS evaluation should be an integral part of the standard assessment of male patients with LUTS as well as a new domain in clinical
and basic research.
Keyword :
Metabolic syndrome, Urinary tract, Benign prostatic hyperplasia.